Uxin shares drop 45% as predicted by InvestingPro’s Fair Value model
Investing.com -- INVO Fertility, Inc. (NASDAQ:IVF) stock surged 33% in after-hours trading Friday following the company’s announcement of its intent to acquire Family Beginnings, P.C., a fertility clinic serving patients across Indiana and the Midwest.
The planned acquisition would mark INVO’s second clinic purchase after acquiring Wisconsin Fertility Institute in 2023, advancing the company’s strategy to build a nationwide network of fertility centers. Family Beginnings, founded in the late 1990s, offers a comprehensive range of reproductive services including in vitro fertilization, intrauterine insemination, and INVO’s own intravaginal culture solution, INVOcell.
"Family Beginnings has long been recognized for its exceptional standards of care, and we are thrilled to welcome Dr. James Donahue and his talented team into the INVO family," said Steve Shum, CEO of INVO. Shum noted that Dr. Donahue was an early adopter of the company’s INVOcell technology.
INVO plans to enhance the Indiana clinic by expanding treatment options, investing in infrastructure and technology, integrating digital patient engagement tools, and providing access to its broader network of resources.
The company indicated it executed a term sheet with Dr. Donahue over a month ago and expects to close the transaction in the near term. However, the acquisition remains subject to due diligence, definitive agreements, and customary closing conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.